- Home
- DYN
as 12-17-2024 4:00pm EST
Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy. The company's product candidates are DYNE-101 and DYNE-251, both are in the ongoing phase 1/2 clinical trial.
| Founded: | 1984 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.6B | IPO Year: | 2020 |
| Target Price: | $51.18 | AVG Volume (30 days): | 836.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.66 - $47.45 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Dyne Therapeutics Inc. (DYN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Dec 11 '24 | Sell | $28.12 | 1,455 | $40,914.60 | 127,078 | |
| Beskrovnaya Oxana | DYN | Chief Scientific Officer | Dec 11 '24 | Sell | $28.12 | 2,334 | $65,632.08 | 201,685 | |
| Kersten Dirk | DYN | Director | Dec 6 '24 | Sell | $29.26 | 136,112 | $3,988,016.16 | 5,400,545 | |
| Kersten Dirk | DYN | Director | Dec 4 '24 | Sell | $29.22 | 138,845 | $4,079,360.51 | 5,400,545 | |
| Kersten Dirk | DYN | Director | Dec 2 '24 | Sell | $29.69 | 110,933 | $3,273,008.14 | 5,400,545 | |
| Scalzo Richard William | DYN | SVP, Head of Finance & Admin. | Nov 18 '24 | Sell | $28.20 | 2,735 | $77,127.00 | 127,078 | |
| Beskrovnaya Oxana | DYN | Chief Scientific Officer | Nov 18 '24 | Sell | $28.20 | 2,856 | $80,539.20 | 201,685 | |
| Incerti Carlo | DYN | Director | Nov 18 '24 | Sell | $28.73 | 16,500 | $474,045.00 | 0 | |
| Rhodes Jason P | DYN | Director | Nov 14 '24 | Sell | $33.10 | 782 | $25,884.20 | 5,697,508 | |
| Kersten Dirk | DYN | Director | Nov 13 '24 | Sell | $34.03 | 19,732 | $673,747.50 | 5,400,545 |
Latest Dyne Therapeutics Inc. News
DYN Breaking Stock News: Dive into DYN Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Baird Initiates Dyne Therapeutics at Outperform With $46 Price Target
MT Newswires
22 days ago
RBC Initiates Dyne Therapeutics at Outperform, Speculative Risk With $45 Price Target
Insider Monkey
a month ago
Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts
MT Newswires
a month ago
Dyne Therapeutics' Q3 Loss Narrows
GlobeNewswire
a month ago
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
MT Newswires
2 months ago
JPMorgan Downgrades Dyne Therapeutics to Neutral From Overweight, Adjusts Price Target to $35 From $43
GlobeNewswire
2 months ago
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases
Insider Monkey
2 months ago
Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now
Compare DYN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DYN Dyne Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.